By Chris Wack
ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene.
The two companies will conduct a confirmatory randomized Phase 3 clinical trial, combining BeiGene's tislelizumab and ImmunityBio's Anktiva.
The Phase 3 study aims to confirm the efficacy and safety of the combination, and provide evidence of the potential for these two immunotherapeutic agents to improve overall survival in patients with advanced or metastatic non-small cell lung cancer who have acquired resistance to immune checkpoint inhibitor therapy.
Immunity Bio said that multiple Phase 1 and 2 studies have demonstrated prolonged overall survival with this combination approach, in comparison to historical results with chemotherapy in this patient population.
ImmunityBio will conduct this confirmatory Phase 3 trial globally across multiple sites. When fully enrolled, it is expected to include 462 participants.
The primary endpoint of the study is overall survival, with secondary endpoints including disease control rate, progression-free survival, objective response rate and safety.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 29, 2025 10:44 ET (15:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。